GGrantIndex
← Leaderboards

Betsy C. Herold

Children'S Hospital Med Ctr (Cincinnati)

Google Scholar ↗PubMed ↗ORCID ↗
$27,491,366
Attributed
$36,549,443
Total exposure
28
Grants
22
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $5.3M · FY2005–25
$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$66,090,127 · 31

By mechanism

U19$37,485,725 · 12
R01$23,615,102 · 8
R44$2,000,000 · 1
R33$1,449,892 · 1
P01$560,470 · 2
R21$456,500 · 1

Top collaborators

Others in their field

Top investigators on “Infection”

Research focus

InfectionCellsPreventResponseVaginaHiv InfectionsViralSimplexvirusWomanClinical ResearchClinical TrialsGenital SystemPharmaceutical PreparationsMicrobicideIn VitroVirusSamplingFemalePredispositionGenital HerpesTissuesCervicalPathway InteractionsAntiviral Agents

Grant awards (111)

Multi-center Evaluation of the Threat of Established and Emerging Respiratory Viral Infections in Pediatric Transplant Recipients$1,502,393
R01 · FY2025 · AI
Mechanisms Underlying the HIV-HSV-2 Syndemic$794,526
R01 · FY2025 · AI · contact PI
Optimizing the Generation of Monoclonal Antibodies for Prevention and Treatment of HSV Disease$594,071
R01 · FY2025 · AI · contact PI
The Unexpected Role of TNFRSF14 Signaling in Promoting Antibody-Dependent Cell-Mediated Cytotoxicity$493,920
R01 · FY2025 · AI · contact PI
Optimizing the Generation of Monoclonal Antibodies for Prevention and Treatment of HSV Disease$603,661
R01 · FY2024 · AI · contact PI
Mechanisms Underlying the HIV-HSV-2 Syndemic$567,690
R01 · FY2024 · AI · contact PI
Mechanisms Underlying the HIV-HSV-2 Syndemic$273,415
R01 · FY2024 · AI · contact PI
Multi-center Evaluation of the Threat of Established and Emerging Respiratory Viral Infections in Pediatric Transplant Recipients$1
R01 · FY2024 · AI
Multi-center Evaluation of the Threat of Established and Emerging Respiratory Viral Infections in Pediatric Transplant Recipients$842,739
R01 · FY2023 · AI
Optimizing the Generation of Monoclonal Antibodies for Prevention and Treatment of HSV Disease$628,100
R01 · FY2023 · AI · contact PI
Impact of the vaginal microbiome on topical HIV pre-exposure prophylaxis (PrEP)$536,541
R01 · FY2023 · HD · contact PI
Multi-center Evaluation of the Threat of Established and Emerging Respiratory Viral Infections in Pediatric Transplant Recipients$845,245
R01 · FY2022 · AI
Impact of the vaginal microbiome on topical HIV pre-exposure prophylaxis (PrEP)$533,354
R01 · FY2022 · HD · contact PI
Mechanisms Underlying the HIV-HSV-2 Syndemic$483,050
R01 · FY2022 · AI · contact PI
Multi-center Evaluation of the Threat of Established and Emerging Respiratory Viral Infections in Pediatric Transplant Recipients$675,979
R01 · FY2021 · AI
Mechanisms Underlying the HIV-HSV-2 Syndemic$488,089
R01 · FY2021 · AI · contact PI
Impact of the vaginal microbiome on topical HIV pre-exposure prophylaxis (PrEP)$463,992
R01 · FY2021 · HD · contact PI
Multi-center evaluation of the threat of established and emerging respiratory viral infections in pediatric transplant recipients$262,298
R01 · FY2021 · AI
Impact of the vaginal microbiome on topical HIV pre-exposure prophylaxis (PrEP)$569,255
R01 · FY2020 · HD · contact PI
Mechanisms Underlying the HIV-HSV-2 Syndemic$509,551
R01 · FY2020 · AI · contact PI
Attenuated HSV Vaccines That Induce Protective Mucosal Antibodies$778,075
R01 · FY2019 · AI
Impact of the vaginal microbiome on topical HIV pre-exposure prophylaxis (PrEP)$512,164
R01 · FY2019 · HD · contact PI
Mechanisms Underlying the HIV-HSV-2 Syndemic$494,568
R01 · FY2019 · AI · contact PI
Mechanisms Underlying the HIV-HSV-2 Syndemic$2,743
R01 · FY2019 · AI · contact PI
Attenuated HSV Vaccines That Induce Protective Mucosal Antibodies$718,769
R01 · FY2018 · AI
Mechanisms Underlying the HIV-HSV-2 Syndemic$518,436
R01 · FY2018 · AI · contact PI
Attenuated HSV Vaccines That Induce Protective Mucosal Antibodies$460,950
R01 · FY2018 · AI
Drug at the Right Place & Concentration: Optimizing Combination Vaginal Ring PrEP$1,536,095
U19 · FY2017 · AI · contact PI
Drug at the Right Place & Concentration: Optimizing Combination Vaginal Ring PrEP$911,260
U19 · FY2017 · AI · contact PI
Attenuated HSV Vaccines That Induce Protective Mucosal Antibodies$773,296
R01 · FY2017 · AI
Administrative Core$737,765
U19 · FY2017 · AI · contact PI
Impact of Mucosal Immune Enviroment and semen on Prep and PD$306,518
U19 · FY2017 · AI · contact PI
Impact of Mucosal Immune Enviroment and semen on Prep and PD$183,580
U19 · FY2017 · AI · contact PI
Administrative Core$163,840
U19 · FY2017 · AI · contact PI
Drug at the Right Place & Concentration: Optimizing Combination Vaginal Ring PrEP$2,652,240
U19 · FY2016 · AI · contact PI
Attenuated HSV Vaccines That Induce Protective Mucosal Antibodies$791,681
R01 · FY2016 · AI
Impact of Mucosal Immune Enviroment and semen on Prep and PD$442,071
U19 · FY2016 · AI · contact PI
Administrative Core$288,020
U19 · FY2016 · AI · contact PI
Drug at the Right Place & Concentration: Optimizing Combination Vaginal Ring PrEP$1,808,691
U19 · FY2015 · AI · contact PI
Drug at the Right Place & Concentration: Optimizing Combination Vaginal Ring PrEP$904,345
U19 · FY2015 · AI · contact PI
Impact of Mucosal Immune Enviroment and semen on Prep and PD$220,295
U19 · FY2015 · AI · contact PI
Impact of Mucosal Immune Enviroment and semen on Prep and PD$162,047
U19 · FY2015 · AI · contact PI
Administrative Core$154,991
U19 · FY2015 · AI · contact PI
Administrative Core$113,999
U19 · FY2015 · AI · contact PI
Drug at the Right Place & Concentration: Optimizing Combination Vaginal Ring Pr*$2,686,508
U19 · FY2014 · AI · contact PI
Continuing Development of PPCM Vaginal Contraceptive Microbicide$1,000,000
R44 · FY2014 · AI
Impact of HSV-2 on Female Genital Tract Mucosal Immunity & HIV Infection$611,790
R01 · FY2014 · AI · contact PI
Impact of Mucosal Immune Enviroment and semen on Prep and PD$394,091
U19 · FY2014 · AI · contact PI
Administrative Core$337,630
U19 · FY2014 · AI · contact PI
Impact of HSV-2 on Female Genital Tract Mucosal Immunity & HIV Infection$44,471
R01 · FY2014 · AI · contact PI
Drug at the Right Place & Concentration: Optimizing Combination Vaginal Ring Pr*$2,677,669
U19 · FY2013 · AI · contact PI
Continuing Development of PPCM Vaginal Contraceptive Microbicide$1,000,000
R44 · FY2013 · AI
Impact of HSV-2 on Female Genital Tract Mucosal Immunity & HIV Infection$568,473
R01 · FY2013 · AI · contact PI
Administrative Core$420,646
U19 · FY2013 · AI · contact PI
Impact of Mucosal Immune Enviroment and semen on Prep and PD$396,948
U19 · FY2013 · AI · contact PI
Impact of HSV-2 on Female Genital Tract Mucosal Immunity & HIV Infection$105,392
R01 · FY2013 · AI · contact PI
Intravaginal Ring Delivery of Safe & Effective Microbicides to Prevent HIV & HSV$2,695,644
U19 · FY2012 · AI · contact PI
Administrative Core$631,462
U19 · FY2012 · AI · contact PI
Impact of HSV-2 on Female Genital Tract Mucosal Immunity & HIV Infection$623,923
R01 · FY2012 · AI · contact PI
Efficacy & Safety of Multitargeted Combination Microbicides to Prevent HIV & HSV$574,983
U19 · FY2012 · AI · contact PI
Novel Mucosal Models Predictive of Microbicide Safety$470,988
R33 · FY2012 · AI · contact PI
Intravaginal Ring Delivery of Safe & Effective Microbicides to Prevent HIV & HSV$1,850,988
U19 · FY2011 · AI · contact PI
Intravaginal Ring Delivery of Safe & Effective Microbicides to Prevent HIV & HSV$1,811,656
U19 · FY2011 · AI · contact PI
Impact of HSV-2 on Female Genital Tract Mucosal Immunity & HIV Infection$600,170
R01 · FY2011 · AI · contact PI
Novel Mucosal Models Predictive of Microbicide Safety$480,904
R33 · FY2011 · AI · contact PI
Efficacy & Safety of Multitargeted Combination Microbicides to Prevent HIV & HSV$417,164
U19 · FY2011 · AI · contact PI
Administrative Core$161,303
U19 · FY2011 · AI · contact PI
Intravaginal Ring Delivery of Safe & Effective Microbicides to Prevent HIV & HSV$2,043,371
U19 · FY2010 · AI · contact PI
Impact of HSV-2 on Female Genital Tract Mucosal Immunity & HIV Infection$576,380
R01 · FY2010 · AI · contact PI
Novel Mucosal Models Predictive of Microbicide Safety$498,000
R33 · FY2010 · AI · contact PI
Efficacy & Safety of Multitargeted Combination Microbicides to Prevent HIV & HSV$493,719
U19 · FY2010 · AI · contact PI
Role of Calcium Signaling in HSV-2 Invasion$408,400
R56 · FY2010 · AI · contact PI
Administrative Core$164,696
U19 · FY2010 · AI · contact PI
Intravaginal Ring Delivery of Safe & Effective Microbicides to Prevent HIV & HSV$1,680,903
U19 · FY2009 · AI · contact PI
Efficacy & Safety of Multitargeted Combination Microbicides to Prevent HIV & HSV$674,304
U19 · FY2009 · AI · contact PI
Role of Calcium Signaling in HSV-2 Invasion$347,418
R01 · FY2009 · AI · contact PI
Antimicrobial Peptides, Genital HSV & HIV Co-Infection$315,163
R01 · FY2009 · AI · contact PI
Novel Mucosal Models Predictive of Microbicide Safety$228,250
R21 · FY2009 · AI · contact PI
Novel microbicides to prevent and treat HSV$129,369
U19 · FY2009 · AI · contact PI
Role of Calcium Signaling in HSV-2 Invasion$347,418
R01 · FY2008 · AI · contact PI
Antimicrobial Peptides, Genital HSV & HIV Co-Infection$328,391
R01 · FY2008 · AI · contact PI
Novel Mucosal Models Predictive of Microbicide Safety$228,250
R21 · FY2008 · AI · contact PI
Novel microbicides to prevent and treat HSV$121,588
U19 · FY2008 · AI · contact PI
MUCOSAL IMMUNE RESPONSE TO GENITAL HSV PRE- AND POST-TREATMENT$21,737
M01 · FY2008 · RR · contact PI
Antimicrobial Peptides, Genital HSV & HIV Co-Infection$500,957
R01 · FY2007 · AI · contact PI
Role of Calcium Signaling in HSV-2 Invasion$293,206
R01 · FY2007 · AI · contact PI
Novel microbicides to prevent and treat HSV$124,996
U19 · FY2007 · AI · contact PI
Role of Calcium Signaling in HSV-2 Invasion$64,782
R01 · FY2007 · AI · contact PI
Antimicrobial Peptides, Genital HSV & HIV Co-Infection$64,454
R01 · FY2007 · AI · contact PI
SAFETY OF COMBINATION MICROBICIDES IN HERPES AND HIV MODEL$32,810
M01 · FY2007 · RR · contact PI
MUCOSAL IMMUNE RESPONSE TO GENITAL HSV PRE- AND POST TREATMENT$28,713
M01 · FY2007 · RR · contact PI
IMMUNE RESPONSES TO INFLUENZA VACCINE IN PEDIATRIC LIVER TRANSPLANT PATIENTS$1,824
M01 · FY2007 · RR · contact PI
Multitargeted Microbicide Combinations to Block HIV$2
U19 · FY2007 · AI · contact PI
Multitargeted Microbicide Combinations to Block HIV$830,132
U19 · FY2006 · HD · contact PI
Antimicrobial Peptides, Genital HSV & HIV Co-Infection$402,411
R01 · FY2006 · AI · contact PI
Role of Calcium Signaling in HSV-2 Invasion$372,414
R01 · FY2006 · AI · contact PI
Novel microbicides to prevent and treat HSV$129,014
U19 · FY2006 · AI · contact PI
IMMUNE RESPONSES TO INFLUENZA VACCINE IN PEDIATRIC LIVER TRANSPLANT PATIENTS$28,954
M01 · FY2006 · RR · contact PI
Multitargeted Microbicide Combinations to Block HIV$1,572,025
U19 · FY2005 · HD
Antimicrobial Peptides, Genital HSV &HIV Co-Infection$365,337
R01 · FY2005 · AI
Role of Calcium Signaling in HSV-2 Invasion$364,000
R01 · FY2005 · AI
Multitargeted Microbicide Combinations to Block HIV$1,278,205
U19 · FY2004 · HD
Multitargeted Microbicide Combinations to Block HIV$1,243,027
U19 · FY2003 · HD
Multitargeted Microbicide Combinations to Block HIV$1,357,925
U19 · FY2002 · HD
ANTIMICROBIALS AGAINST HSV AND HIV-1 INFECTION$180,480
P01 · FY2002 · AI
Safety of Combination Microbicides in Herpes Models$0
U19 · FY2002 · HD
Mechanism of SAMMA against HSV: key cofactor for HIV$0
P01 · FY2002 · HD
ANTIMICROBIALS AGAINST HSV AND HIV-1 INFECTION$180,480
P01 · FY2001 · AI
Mechanism of SAMMA against HSV: key cofactor for HIV$0
P01 · FY2001 · HD
ANTIMICROBIALS AGAINST HSV AND HIV-1 INFECTION$199,510
P01 · FY2000 · AI
ANTIMICROBIALS AGAINST HSV AND HIV-1 INFECTION$0
P01 · FY2000 · AI